Uncategorized

MMS Holdings (MMS), an award-winning, data-focused contract research organization (CRO), announced today that it has been selected by MAPS Public Benefit Corporation (MAPS PBC) as its contract research organization for the development of a New Drug Application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD). This announcement comes on PTSD Awareness Day as the confirmatory Phase 3 trial MAPP2, the second of two Phase 3 trials conducted by MAPS PBC, finished enrollment in early May. 

MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to announce a strategic partnership with Medidata, a Dassault Systèmes company, to provide clients a full range of solutions for clinical data management (CDM) and decentralized clinical trial solutions (DCTs), including Medidata’s unified platform and Rave EDC (Electronic Data Capture).

MMS Holdings Inc. (MMS) – an award-winning, data-focused contract research organization (CRO) – announced a collaboration with THREAD® as its partner of choice for its decentralized clinical trials platform (DCT) and DCT-enabled services. THREAD’s next-generation DCT technology enables faster, more efficient clinical trials while improving access for research participants with higher quality data capture across the life cycle of a study.

MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, biopharma executive, as Principal Medical Director of Global Drug Safety and Pharmacovigilance to its team.

CANTON, Mich. (2/2/2022) – MMS Holdings, a Data CRO, was recognized in the 2022 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates.  MMS, a minority and woman-owned business in Canton, was the only Michigan Pharma organization on the national list.

MMS Holdings announced a restructuring of their consulting services with the launch of a Project Advisory Services Unit to meet the needs of many small to mid-sized organizations in immediate, short and long-term needs for senior-level guidance, specialized consulting, and advisory services.

MMS Holdings is pleased to announce its selection as Best Contract Research Organization – Specialist Providers in the 2021 Scrip Awards. The Scrip Awards, held annually by London-based Informa Pharma Intelligence, honors outstanding achievements of organizations in the pharmaceutical, biotech and allied industries.

Former Astellas Pharma VP of Biostatistics Joins MMS as Principal Advisor of Biostatistics and Submissions Planning. Dr. Chartier has held positions at Astellas Pharma, Novartis, Wyeth, Pfizer, and United BioSource Corporation across various statistics, biometrics, and biostatistics functions.

CANTON, Mich. (11/15/2021) – MMS has been named a 2021 award winner of the Michigan Top Workplaces by the Detroit Free Press Top Workplaces. The award is based solely on employee feedback from an anonymous survey measuring 15 culture drivers that are critical to the success of any organization, including alignment, execution, and connection, among others. … MMS Holdings is the Winner of The Michigan Top Workplaces 2021 Award

MMS Holdings provided regulatory strategy support to Praxis Bioresearch in the development of a therapeutic for apathy in Alzheimer’s disease. This comes as Praxis was awarded a $2.9 Million Fast-Track SBIR Grant to advance the company’s lead development candidate PRX-P4-003.

MMS Holdings announced the release of SmartStart™ a Tech-Enabled Templates to reduce time and effort in the document content creation process while increasing the quality of deliverables.

MMS announced today the launch of its pro-bono support program aimed at advancing research for ultra-rare diseases. Within this program, MMS will select from patient advocacy groups with demonstrable need and will provide complimentary regulatory assistance.